Separating Promise From Proof

By: Daniel J. Cognetti, M.D. 
AANA Communications and Technology Committee  

Peptide-based therapies are a hot topic in sports medicine. Patients are hearing about BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, GHK-Cu and other compounds on podcasts, social media, online recovery forums, supplement websites and in wellness clinics. They are then bringing these questions into clinic, often asking whether these products can improve wound healing, tendon repair, muscle growth or recovery after injury or surgery. As sports medicine surgeons, we should share our patients’ interest in treatments that may improve healing and recovery, but our recommendations must remain grounded in evidence, safety and clinical judgment. 

The challenge is that many research peptides are discussed as though they are ready for clinical use. However, an interesting physiologic mechanism is only the starting point for a useful medication. Before recommending any therapy, clinicians need to know whether it is manufactured consistently, absorbed predictably, dosed appropriately, studied in humans, safe for the intended patient population and ultimately beneficial. For many peptides marketed for recovery and performance, those questions remain unanswered. 

BPC-157 is a useful case study for this broader population of medications. It is a 15-amino acid peptide derived from a gastric protein fragment and has generated interest because preclinical studies suggest potential effects on angiogenesis, collagen organization, inflammation and tissue repair. It has been promoted for tendon, ligament, muscle, bone, gastrointestinal and postoperative healing. For patients and athletes hoping to recover faster, these claims are understandably attractive. 

The problem is that the science has not kept pace with the anecdotes and marketing. 

One of BPC-157’s most interesting features is its reported gastric stability. Most peptides are rapidly degraded in the gastrointestinal tract, which is why many peptides require injection or specialized formulation. BPC-157 appears relatively resistant to acidic and proteolytic gastric conditions, making oral delivery an intriguing possibility. However, surviving the stomach is not the same as becoming an effective oral medication. A peptide still has to cross the gut barrier, avoid excessive first-pass metabolism, reach target tissues at meaningful concentrations and produce a clinical benefit. For BPC-157, these steps have not been adequately characterized in human clinical studies. Animal pharmacokinetic studies also suggest a short plasma half-life (30 minutes) and variable intramuscular bioavailability, making appropriate dosing and treatment duration difficult to define. 

Human clinical evidence remains sparse. Published data are limited to small reports with disparate uses, including intra-articular injections, urinary bladder and gastrointestinal applications and intravenous administration in a two-patient series. A registered Phase I trial intended to evaluate BPC-157 safety and pharmacokinetics in healthy volunteers was terminated without published study results. That study could have provided foundational dosing and safety information. Instead, its disappearance leaves a major evidence gap.

These limitations are not unique to BPC-157. They reflect the broader problem with many research peptides currently marketed for recovery and performance. BPC-157 still has no approved pharmaceutical-grade formulation, no validated dosing regimen, no standardized route of administration and very limited human evidence. None of this proves that it is ineffective. It means we do not yet know whether it is effective, safe, properly dosed, reliably absorbed or appropriately manufactured for clinical use.

Product quality further complicates the issue. Many research peptides are purchased online or through nontraditional channels, where purity, concentration, sterility and batch consistency may be uncertain. Without reliable independent testing, contamination, impurities and heavy metal exposure are also risks. These concerns are especially relevant when products are injected or used by postoperative patients. 

There are also important anti-doping and military implications that surgeons should be aware of. Many peptides and peptide hormones are prohibited by the World Anti-Doping Agency (WADA) and servicemembers have a similar prohibitory list. For tested athletes and military patients, peptide use is not only a medical issue, but can affect their eligibility, readiness and career status. 

So, what should sports medicine surgeons tell patients? 

At this time, we cannot recommend BPC-157 or similar research peptides for wound healing, muscle growth, injury recovery, postoperative healing or performance enhancement in the absence of clinical evidence. That recommendation does not require dismissing the promise. These therapies are interesting and worth continued study. They may eventually have a role in orthopaedics and sports medicine, but promise should not be conflated with proof, and gray-market access is not the same as clinical readiness. 

Patients will continue to ask about peptides. Our role is to separate excitement from evidence. BPC-157 may have survived the stomach, but it has not yet survived the standards required for routine recommendation. 

Resources 

Mateescu, D.M., Gavrilescu, D.M., Constantinescu, F.E., Oancea, C., Ilie, A.C., Folescu, R., Popa, M.D., Iurciuc, S., Muresan, C.O., Enache, A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026 May 20;18(5):625. 

Interested in More Clinical Resources?